Publicaciones en las que colabora con EMILIA RODEÑO ORTIZ ZARATE (27)

2023

  1. Descending mediastinitis that simulates a pharyngo-laryngeal neoplasm

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 193-194

  2. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500

  3. Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

    EJNMMI Physics, Vol. 10, Núm. 1

  4. The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis

    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.., Vol. 67, Núm. 1, pp. 83-92

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

    Physica Medica, Vol. 88, pp. 45-52

2020

  1. Feasibility and limitations of quantitative SPECT for 223Ra

    Physics in Medicine and Biology, Vol. 65, Núm. 8

2019

  1. Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively

    Physica Medica, Vol. 65, pp. 143-149

  2. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT

    European Journal of Cancer Care, Vol. 28, Núm. 5

2018

  1. BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?

    Cirugia Espanola, Vol. 96, Núm. 5, pp. 276-282

  2. Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with 223Ra

    Physics in Medicine and Biology, Vol. 63, Núm. 14

  3. Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 1, pp. 20-27

  4. Técnicas complementarias del diagnóstico neurológico

    Neurología (Elsevier), pp. 21-40

2016

  1. PET/CT imaging with 18F-FDG in Castleman disease

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 35, Núm. 3, pp. 200-201

  2. Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer

    Medical Physics, Vol. 43, Núm. 10, pp. 5279-5287

2013

  1. Pseudoaneurisma arterial como falso positivo de infección en la gammagrafía ósea y con leucocitos marcados en un paciente con prótesis total de cadera

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 32, Núm. 5, pp. 334-335

2012

  1. Proceso diagnóstico del tromboembolismo

    Medicina nuclear en la práctica clínica (Aula Médica Ediciones), pp. 381-400

2011

  1. EVIDENCIAS EN MEDICINA NUCLEAR. Selección de publicaciones, Enero-Junio 2010

    Revista española de medicina nuclear, Vol. 30, Núm. 2, pp. 124-133

2010

  1. Evidencias en Medicina Nuclear. Seleccion de publicaciones Julio-Diciembre 2009

    Revista española de medicina nuclear, Vol. 29, Núm. 4, pp. 211-219

  2. Evidencias en medicina nuclear. Seleccion de publicaciones Enero-Junio 2009

    Revista española de medicina nuclear, Vol. 29, Núm. 1, pp. 42-49